This is a long term safety study for patients who have completed a Novartis sponsored asciminib study and are judged by the investigator to benefit from continued treatment
1 Primary · 1 Secondary · Reporting Duration: 5 years
Experimental Treatment
347 Total Participants · 8 Treatment Groups
Primary Treatment: Asciminib 40 mg BID single agent group · No Placebo Group · Phase 4
Age 18+ · All Participants · 3 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: